Molecular mechanisms of fentanyl mediated β-arrestin biased signaling

The development of novel analgesics with improved safety profiles to combat the opioid epidemic represents a central question to G protein coupled receptor structural biology and pharmacology: What chemical features dictate G protein or β-arrestin signaling? Here we use adaptively biased molecular dynamics simulations to determine how fentanyl, a potent β-arrestin biased agonist, activates the μ-opioid receptor (μOR). The resulting fentanyl-bound pose provides rational insight into a wealth of historical structure-activity-relationship on its chemical scaffold. We found that fentanyl and the synthetic opioid peptide DAMGO require M153 to induce β-arrestin coupling, while M153 was dispensable for G protein coupling. We propose and validate a mechanism where the n-aniline ring of fentanyl mediates μOR β-arrestin through a novel M153 “microswitch” by synthesizing fentanyl-based derivatives that exhibit complete, clinically desirable, G protein biased coupling. Together, these results provide molecular insight into fentanyl mediated β-arrestin biased signaling and a rational framework for further optimization of fentanyl-based analgesics with improved safety profiles. Author Summary The global opioid crisis has drawn significant attention to the risks associated with over-use of synthetic opioids. Despite the public attention, and perhaps in-line with the profit-based incentives of the pharmaceutical industry, there is no public structure of mu-opioid receptor bound to fentanyl or fentayl derivatives. A publicly available structure of the complex would allow open-source development of safer painkillers and synthetic antagonists. Current overdose antidotes, antagonists, require natural products in their synthesis which persists a sizable barrier to market and develop better antidotes. In this work we use advance molecular dynamics techniques to obtain the bound geometry of mu-opioid receptor with fentanyl (and derivatives). Based on our in-silico structure, we synthesized and tested novel compounds to validate our predicted structure. Herein we report the bound state of several dangerous fentanyl derivatives and introduce new derivatives with signaling profiles that may lead to lower risk of respiratory depression.

[1]  Bradley M Dickson,et al.  A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4. , 2016, The Journal of chemical physics.

[2]  H. Xu,et al.  Molecular mechanisms of fentanyl mediated β-arrestin biased signaling , 2020, PLoS computational biology.

[3]  G. Loew,et al.  Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors , 1992 .

[4]  Brock F. Binkowski,et al.  NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. , 2016, ACS chemical biology.

[5]  William J. Allen,et al.  DOCK 6: Impact of new features and current docking performance , 2015, J. Comput. Chem..

[6]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[7]  V. Hruby,et al.  Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. , 2006, Bioorganic & medicinal chemistry letters.

[8]  Bradley M Dickson,et al.  Overfill Protection and Hyperdynamics in Adaptively Biased Simulations. , 2017, Journal of chemical theory and computation.

[9]  R. A. Moyer,et al.  An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization , 2007, Molecular Pharmacology.

[10]  M. Connor,et al.  OPIOID RECEPTOR SIGNALLING MECHANISMS , 1999, Clinical and experimental pharmacology & physiology.

[11]  Lei Shi,et al.  What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands? , 2015, Pharmacological Reviews.

[12]  Massimiliano Bonomi,et al.  PLUMED 2: New feathers for an old bird , 2013, Comput. Phys. Commun..

[13]  Isuru R. Kumarasinghe,et al.  Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. , 2009, Bioorganic & Medicinal Chemistry.

[14]  Marlene T. Kim,et al.  Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking , 2018, PloS one.

[15]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[16]  Henry Lin,et al.  Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.

[17]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[18]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[19]  L. Bohn,et al.  Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics , 2017, Cell.

[20]  S. Breeden,et al.  Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. , 2004, European journal of pharmacology.

[21]  Lawrence Scholl,et al.  Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017 , 2018, MMWR. Morbidity and mortality weekly report.

[22]  V. Durmaz,et al.  A nontoxic pain killer designed by modeling of pathological receptor conformations , 2017, Science.

[23]  L. Bohn,et al.  Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  Irena Melnikova,et al.  Pain market , 2010, Nature Reviews Drug Discovery.

[25]  Davide Provasi,et al.  How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways. , 2016, Biochemistry.

[26]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[27]  B. Mayer,et al.  An Efficient, Optimized Synthesis of Fentanyl and Related Analogs , 2014, PloS one.

[28]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[29]  D. E. Nichols,et al.  Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.

[30]  Vadim Cherezov,et al.  Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.

[31]  Bradley M Dickson Approaching a parameter-free metadynamics. , 2011, Physical review. E, Statistical, nonlinear, and soft matter physics.

[32]  H. Xu,et al.  The structural basis of the dominant negative phenotype of the Gαi1β1γ2 G203A/A326S heterotrimer , 2016, Acta Pharmacologica Sinica.

[33]  Albert C. Pan,et al.  Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.

[34]  Nancy Cheng,et al.  A cellular chemical probe targeting the chromodomains of Polycomb Repressive Complex 1 , 2015, Nature chemical biology.

[35]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[36]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[37]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[38]  M. Caron,et al.  Differential Mechanisms of Morphine Antinociceptive Tolerance Revealed in βArrestin-2 Knock-Out Mice , 2002, The Journal of Neuroscience.

[39]  J. Violin,et al.  Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. , 2013, Journal of medicinal chemistry.

[40]  Ping Liu,et al.  Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist , 2018, Cell Discovery.

[41]  F. Davidson,et al.  Synthesis of some conformationally restricted analogues of fentanyl. , 1977, Journal of medicinal chemistry.

[42]  D. Whiting,et al.  Synthesis and biological evaluation of fentanyl acrylic derivatives , 2017 .

[43]  Albert C. Pan,et al.  Activation mechanism of the β2-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.

[44]  Z. Todorović,et al.  Fentanyl analogs: structure-activity-relationship study. , 2009, Current medicinal chemistry.

[45]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[46]  S. Husbands,et al.  The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception , 2018, British journal of pharmacology.

[47]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.

[48]  Marc G. Caron,et al.  μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.

[49]  V. Hruby,et al.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. , 2014, Future medicinal chemistry.

[50]  Naomi R. Latorraca,et al.  Structure of the μ Opioid Receptor-Gi Protein Complex , 2018, Nature.

[51]  N. Volkow,et al.  The Role of Science in Addressing the Opioid Crisis. , 2017, The New England journal of medicine.

[52]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[53]  K. Dill,et al.  Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". , 2009, Structure.

[54]  D. Ferguson,et al.  Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. , 2000, Journal of medicinal chemistry.

[55]  R. Gainetdinov,et al.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. , 2000, Nature.

[56]  Sean Hughes,et al.  Clustering by Fast Search and Find of Density Peaks , 2016 .

[57]  Rafael C. Bernardi,et al.  Enhanced sampling techniques in molecular dynamics simulations of biological systems. , 2015, Biochimica et biophysica acta.

[58]  G. Loew,et al.  Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. , 1992, European journal of pharmacology.

[59]  Stephen M. Husbands,et al.  Structural insights into μ-opioid receptor activation , 2015, Nature.